Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE versus POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5 AND SODIUM CHLORIDE 0 45 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNESIUM SULFATE versus POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5 AND SODIUM CHLORIDE 0 45 IN PLASTIC CONTAINER.
MAGNESIUM SULFATE vs POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate acts as a physiological calcium channel blocker. It inhibits calcium influx into presynaptic nerve terminals, reducing acetylcholine release at the neuromuscular junction and decreasing muscle contraction. It also antagonizes NMDA receptors and stabilizes neuronal membranes.
Potassium is the major intracellular cation; it is essential for maintenance of membrane potential, nerve impulse transmission, cardiac contractility, and skeletal muscle function. Dextrose provides calories and may decrease protein catabolism. Sodium chloride helps maintain extracellular fluid volume and electrolyte balance.
IV: Loading dose 4-6 g over 20-30 minutes, followed by maintenance infusion 1-2 g/hour for seizure prophylaxis in severe preeclampsia/eclampsia. IM: 4-8 g deep IM initially, then 4 g every 4 hours as needed.
Intravenous infusion; dose determined by serum potassium levels and patient condition; typical maintenance: 10-20 mEq potassium per hour; maximum infusion rate: 20 mEq/hour (not to exceed 1 mEq/kg/hour); concentration not to exceed 80 mEq/L via peripheral line. Each 1 L of this product contains 5 mEq potassium chloride, 50 g dextrose, and 77 mEq sodium chloride.
None Documented
Clinical Note
moderateMagnesium sulfate + Gatifloxacin
"The serum concentration of Gatifloxacin can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateMagnesium sulfate + Rosoxacin
"The serum concentration of Rosoxacin can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateMagnesium sulfate + Levofloxacin
"The serum concentration of Levofloxacin can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateNone Documented
Terminal elimination half-life approximately 4-6 hours in patients with normal renal function; prolonged to 12-24 hours or more in renal impairment, necessitating dose adjustment
Not applicable for endogenous potassium; infused potassium distributes with a rapid initial phase (~1 h) and a slower terminal phase (~8-12 h) reflecting cellular equilibration
Primarily renal (90-95% as unchanged drug); minor biliary/fecal (<5%)
Renal: >90% as potassium ion; minor fecal loss <10%
Category C
Category A/B
Electrolyte
Electrolyte
Magnesium sulfate + Trovafloxacin
"The serum concentration of Trovafloxacin can be decreased when it is combined with Magnesium sulfate."